On Nov 07, major Wall Street analysts update their ratings for $Tandem Diabetes Care (TNDM.US)$, with price targets ranging from $37 to $65.
Morgan Stanley analyst Patrick Wood maintains with a hold rating, and maintains the target price at $45.
TD Cowen analyst Josh Jennings maintains with a buy rating, and maintains the target price at $45.
Baird analyst Jeff Johnson maintains with a hold rating, and adjusts the target price from $39 to $37.
RBC Capital analyst Shagun Singh Chadha maintains with a buy rating, and maintains the target price at $65.
Piper Sandler analyst Matthew O'Brien maintains with a buy rating, and maintains the target price at $55.
Furthermore, according to the comprehensive report, the opinions of $Tandem Diabetes Care (TNDM.US)$'s main analysts recently are as follows:
The firm noted that while Tandem Diabetes' Q3 revenue surpassed expectations, this was partially due to the timing of U.S. supplies and international distributor orders, with the volume of Q3 pump shipments in the U.S. aligning with the firm's projections.
Here are the latest investment ratings and price targets for $Tandem Diabetes Care (TNDM.US)$ from 5 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
